Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cancer Pain - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Cancer Pain - Pipeline Review, H2 2015', provides an overview of the Cancer Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Cancer Pain Overview 8 Therapeutics Development 9 Pipeline Products for Cancer Pain - Overview 9 Pipeline Products for Cancer Pain - Comparative Analysis 10 Cancer Pain - Therapeutics under Development by Companies 11 Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13 Cancer Pain - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Cancer Pain - Products under Development by Companies 18 Cancer Pain - Products under Investigation by Universities/Institutes 20 Cancer Pain - Companies Involved in Therapeutics Development 21 Amgen Inc. 21 Amorsa Therapeutics Inc. 22 AngioChem Inc. 23 Aphios Corporation 24 AstraZeneca Plc 25 BCN Peptides, S.A. 26 Benitec Biopharma Limited 27 BioDelivery Sciences International, Inc. 28 ChironWells GmbH 29 Daiichi Sankyo Company, Limited 30 Fujimoto Pharmaceutical Corporation 31 Grunenthal GmbH 32 GW Pharmaceuticals Plc 33 Hisamitsu Pharmaceutical Co., Inc. 34 Immupharma Plc 35 IntelGenx Corp. 36 Kolon Life Science, Inc. 37 Nektar Therapeutics 38 Neurocentrx Pharma Ltd. 39 Orion Oyj 40 Pain Therapeutics, Inc. 41 Pfizer Inc. 42 Pharmaleads 43 PsychoGenics, Inc. 44 Recordati S.p.A. 45 Ribomic Inc. 46 Virobay Inc. 47 WEX Pharmaceuticals Inc. 48 Winston Pharmaceuticals, Inc. 49 Zynerba Pharmaceuticals, Inc. 50 Cancer Pain - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 AMS-410 ER12 - Drug Profile 61 ANG-2002 - Drug Profile 62 BBI-11008 - Drug Profile 63 buprenorphine hydrochloride - Drug Profile 64 calpastatin - Drug Profile 65 cebranopadol - Drug Profile 66 crotalphine - Drug Profile 68 DD-04107 - Drug Profile 69 dexmedetomidine hydrochloride - Drug Profile 70 dronabinol - Drug Profile 72 dronabinol - Drug Profile 73 Drug for Cancer Neuropathic Pain - Drug Profile 74 fentanyl - Drug Profile 75 fentanyl citrate - Drug Profile 76 fentanyl citrate - Drug Profile 77 fulranumab - Drug Profile 78 HP-3150 - Drug Profile 81 HS-198 - Drug Profile 82 hydromorphone hydrochloride - Drug Profile 83 IPP-102199 - Drug Profile 84 ketamine hydrochloride ER - Drug Profile 85 KLS-2020 - Drug Profile 86 methadone hydrochloride - Drug Profile 87 nabiximols - Drug Profile 88 Nervarna - Drug Profile 91 NKTR-192 - Drug Profile 93 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 94 PL-265 - Drug Profile 95 Q-201 - Drug Profile 96 QX-314 - Drug Profile 97 RBM-004 - Drug Profile 98 RBM-007 - Drug Profile 99 saracatinib difumarate - Drug Profile 100 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 102 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 103 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 104 tanezumab - Drug Profile 105 Tetrodotoxin - Drug Profile 108 VBY-825 - Drug Profile 110 ZJ-43 - Drug Profile 111 zucapsaicin - Drug Profile 112 ZYN-001 - Drug Profile 114 Cancer Pain - Recent Pipeline Updates 116 Cancer Pain - Dormant Projects 128 Cancer Pain - Discontinued Products 130 Cancer Pain - Product Development Milestones 131 Featured News & Press Releases 131 Appendix 137 Methodology 137 Coverage 137 Secondary Research 137 Primary Research 137 Expert Panel Validation 137 Contact Us 137 Disclaimer 138
List of Tables
Number of Products under Development for Cancer Pain, H2 2015 12 Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2015 13 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 16 Comparative Analysis by Late Stage Development, H2 2015 17 Comparative Analysis by Clinical Stage Development, H2 2015 18 Comparative Analysis by Early Stage Development, H2 2015 19 Comparative Analysis by Unknown Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2015 23 Cancer Pain - Pipeline by Amgen Inc., H2 2015 24 Cancer Pain - Pipeline by Amorsa Therapeutics Inc., H2 2015 25 Cancer Pain - Pipeline by AngioChem Inc., H2 2015 26 Cancer Pain - Pipeline by Aphios Corporation, H2 2015 27 Cancer Pain - Pipeline by AstraZeneca Plc, H2 2015 28 Cancer Pain - Pipeline by BCN Peptides, S.A., H2 2015 29 Cancer Pain - Pipeline by Benitec Biopharma Limited, H2 2015 30 Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2015 31 Cancer Pain - Pipeline by ChironWells GmbH, H2 2015 32 Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 33 Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H2 2015 34 Cancer Pain - Pipeline by Grunenthal GmbH, H2 2015 35 Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H2 2015 36 Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 37 Cancer Pain - Pipeline by Immupharma Plc, H2 2015 38 Cancer Pain - Pipeline by IntelGenx Corp., H2 2015 39 Cancer Pain - Pipeline by Kolon Life Science, Inc., H2 2015 40 Cancer Pain - Pipeline by Nektar Therapeutics, H2 2015 41 Cancer Pain - Pipeline by Neurocentrx Pharma Ltd., H2 2015 42 Cancer Pain - Pipeline by Orion Oyj, H2 2015 43 Cancer Pain - Pipeline by Pain Therapeutics, Inc., H2 2015 44 Cancer Pain - Pipeline by Pfizer Inc., H2 2015 45 Cancer Pain - Pipeline by Pharmaleads , H2 2015 46 Cancer Pain - Pipeline by PsychoGenics, Inc., H2 2015 47 Cancer Pain - Pipeline by Recordati S.p.A., H2 2015 48 Cancer Pain - Pipeline by Ribomic Inc., H2 2015 49 Cancer Pain - Pipeline by Virobay Inc., H2 2015 50 Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H2 2015 51 Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H2 2015 52 Cancer Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 53 Assessment by Monotherapy Products, H2 2015 54 Number of Products by Stage and Target, H2 2015 56 Number of Products by Stage and Mechanism of Action, H2 2015 59 Number of Products by Stage and Route of Administration, H2 2015 61 Number of Products by Stage and Molecule Type, H2 2015 63 Cancer Pain Therapeutics - Recent Pipeline Updates, H2 2015 119 Cancer Pain - Dormant Projects, H2 2015 131 Cancer Pain - Dormant Projects (Contd..1), H2 2015 132 Cancer Pain - Discontinued Products, H2 2015 133
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
